Immunomodulatory functions of type I interferons

被引:0
|
作者
José M. González-Navajas
Jongdae Lee
Michael David
Eyal Raz
机构
[1] Allergy and Immunology,Division of Rheumatology, Department of Medicine
[2] University of California San Diego,Division of Biological Sciences
[3] Biomedical Research Center in Hepatic and Digestive Diseases (CIBERehd),undefined
[4] Instituto de Salud Carlos III,undefined
[5] Fundación para la Investigación en el Hospital General de Alicante,undefined
[6] University of California San Diego,undefined
来源
Nature Reviews Immunology | 2012年 / 12卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Interferons (IFNs) are widely expressed cytokines with strong antiviral properties. There are three main types of IFNs: type I IFNs, type II IFN and type III IFNs. In addition to their role in response to viruses, type I IFNs (mainly IFNα and IFNβ) are induced by bacterial infections.The production of type I IFNs in response to bacterial ligands is mediated through Toll-like receptor (TLR)-dependent and -independent mechanisms. TLR3, TLR4, TLR7 and TLR9 have been linked to the production of type I IFNs. The TLR-independent pathways involve the cytoplasmic nucleic acid sensors retinoic-acid-inducible gene I (RIG-I), melanoma differentiation-associated gene 5 (MDA5), stimulator of interferon genes (STING) and DNA-dependent activator of IRFs (DAI).Type I IFNs activate several Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signalling pathways, which regulate the transcription of target genes. In addition to the classical JAK–STAT signalling pathways, type I IFNs activate other signalling cascades.Type I IFNs mediate the regulatory functions of dendritic cells in the gut and the protective effect of TLR ligands in colonic injury.Activation of type I IFN signalling has an important role in T helper cell differentiation and in the suppressive function of regulatory T cells.Type I IFNs both negatively and positively regulate the activation of different types of inflammasome complex and the production of interleukin-1β.In addition to their role as antiviral cytokines, type I IFNs have a wide range of immunomodulatory effects in response to bacterial infections.Type I IFNs are implicated in different autoimmune and inflammatory conditions, although their role in each condition varies. Some autoimmune diseases are improved by the biological effects of type I IFNs, whereas others benefit from type I IFN inhibition.
引用
收藏
页码:125 / 135
页数:10
相关论文
共 50 条
  • [21] Type I interferons in systemic autoimmunity
    Sozzani, Silvano
    Bosisio, Daniela
    Scarsi, Mirko
    Tincani, Angela
    AUTOIMMUNITY, 2010, 43 (03) : 196 - 203
  • [22] Type I interferons (α/β) in immunity and autoimmunity
    Theofilopoulos, AN
    Baccala, R
    Beutler, B
    Kono, DH
    ANNUAL REVIEW OF IMMUNOLOGY, 2005, 23 : 307 - 336
  • [23] Type I interferons: expression and signalization
    J. Doly
    A. Civas
    S. Navarro
    G. Uze
    Cellular and Molecular Life Sciences CMLS, 1998, 54 : 1109 - 1121
  • [24] Overview of the biology of type I interferons
    Kalliolias, George D.
    Ivashkiv, Lionel B.
    ARTHRITIS RESEARCH & THERAPY, 2010, 12
  • [25] Overview of the biology of type I interferons
    George D Kalliolias
    Lionel B Ivashkiv
    Arthritis Research & Therapy, 12
  • [26] Induction of type I interferons by bacteria
    Monroe, Kathryn M.
    McWhirter, Sarah M.
    Vance, Russell E.
    CELLULAR MICROBIOLOGY, 2010, 12 (07) : 881 - 890
  • [27] Type I interferons in anticancer immunity
    Zitvogel, Laurence
    Galluzzi, Lorenzo
    Kepp, Oliver
    Smyth, Mark J.
    Kroemer, Guido
    NATURE REVIEWS IMMUNOLOGY, 2015, 15 (07) : 405 - 414
  • [28] Signal transduction by type I interferons
    David, M
    BIOTECHNIQUES, 2002, : 58 - 65
  • [29] Type I Interferons in Autoimmune Disease
    Crow, Mary K.
    Olferiev, Mikhail
    Kirou, Kyriakos A.
    ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 14, 2019, 14 : 369 - 393
  • [30] Effects of type I interferons in malaria
    Sebina, Ismail
    Haque, Ashraful
    IMMUNOLOGY, 2018, 155 (02) : 176 - 185